Drug Pipeline Database & Screener

Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-25 minutes.

Showing 552 companies

Screener

Sort

Company Price Change Market Cap Outstanding Shares Short Ratio Updated

Stage

Any... Phase 1a Phase 1 Phase 1b Phase 1/2 Phase 2a Phase 2 Phase 2b Phase 2/3 Phase 3 NDA Filing sNDA Filing BLA Filing PDUFA PDUFA priority review Approved CRL

Indication

Any... 22q11.2 Deletion Syndrome AADC deficiency Abdominal symptom claims (ASC) Achalasia Achondroplasia Achromatopsia Acid sphingomyelinase deficiency (ASMD) Acne Acquired thrombotic thrombocytopenic purpura (aTTP) Acromegaly Actinic keratosis Acute bacterial skin and skin structure infections (ABSSSI) Acute Coronary Syndrome Acute hepatic porphyrias Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Acute myocardial infarction (AMI) Acute otitis externa Acute Promyelocytic Leukemia Acute Respiratory Distress Syndrome Acute-on-Chronic Liver Failure (ACLF) Adenosine deaminase severe combined immunodeficiency (ADA-SCID) Adenovirus ADHD Adrenoleukodystrophy (ALD) Adult Growth Hormone Deficiency (AGHD) Age-related macular degeneration (AMD) Agitation Alcohol Use Disorder Alcohol-induced liver decompensation (AILD) Alcoholic Hepatitis Alcoholic steatohepatitis (ASH) Alopecia areata Alpha-1 Antitrypsin deficiency (AATD) Alport Syndrome Alstrom Syndrome Alzheimer’s disease Ammonia Amyloidosis Amyotrophic Lateral Sclerosis (ALS) Anal cancer Anal fissures Anaphylaxis Androgenetic alopecia (AGA) Androgenic Alopecia Anemia Angelman syndrome Angiosarcoma Animal related Ankylosing spondylitis Anthrax Arginase I deficiency Asthma Atopic dermatitis Atopic keratoconjunctivitis Atrial fibrillation (AF) ATTR (transthyretin amyloidosis) atypical Hemolytic Uremic Syndrome (aHUS) Autism Autism Spectrum Disorder (ASD) Auto-immune Hemolytic Anemia (AIHA) Autoimmune pulmonary alveolar proteinosis (PAP) autosomal dominant retinitis pigmentosa (adRP) Autosomal Recessive Stargardt Disease Axial Spondyloarthritis B-Cell Lymphoma Back pain Bacteremia Bardet-Biedl Syndrome Barth Basal cell carcinoma Batten Disease Behcet's Disease Benign Prostatic Hyperplasia (BPH) Beta-Thalassemia Biliary atresia Biliary Tract Cancer Biosimilar Bipolar depression Bladder cancer Bladder pain syndrome/interstitial cystitis (BPS/IC) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Bleeding Blindness Bowel related Brain cancer Brain injury Breast cancer Bronchiectasis Bulimia Bullous Pemphigoid Bunionectomy C. difficile Infection C3 glomerulopathy (C3G) Cachexia Candida Auris Candidemia Carcinoid Syndrome Carcinoma In-Situ (CIS) Cardiomyopathy Cardiovascular disease Cartilage/Knee Catecholamine-resistant hypotension (CRH) CDKL5 disorder Celiac disease Celluite Cervical cancer Cervical dysplasia Cervical dystonia Charcot-Marie-Tooth disease (CMT) Chemotherapy induced nausea and vomiting (CINV) Chemotherapy-induced neutropenia (CIN) Chikungunya vaccine Chikungunya Virus Infection Cholangiocarcinoma Choroideremia Chronic cough Chronic Dysphonia Chronic idiopathic constipation (CIC) Chronic Kidney Disease-Associated Pruritus Chronic Lymphocytic Leukemia (CLL) Chronic myelogenous leukemia Chronic myelomonocytic leukemia (CMML) Chronic obstructive pulmonary disease (COPD) Chronic Prostatitis Chronic spontaneous urticaria Chronic Urticaria Cold agglutinin disease Colon cancer Colorectal cancer Community-acquired bacterial pneumonia (CABP) Complement-dependent Nephropathies (CDN) Complex regional pain syndrome (CRPS) Complicated intra-abdominal infections (cIAI) Complicated urinary tract infections (cUTI) Condyloma Congenital Adrenal Hyperplasia (CAH) Congenital hyperinsulinism Congenital Myasthenic Syndromes (CMS) Conjunctivitis Connective tissue growth factor (CTGF) Constipation Contact lens Contraception Coronary artery disease (CAD) Coronary microvascular dysfunction (CMD) Cow’s milk protein allergy (CMPA) Crigler-Najjar Critical limb ischemia (CLI) Crohn’s Disease Cushings syndrome Cutaneous fibrosis Cutaneous squamous cell carcinoma Cutaneous T-cell lymphoma (CTCL) Cystic fibrosis Cystinosis Cystinuria Cytomegalovirus (CMV) Danon disease Degenerative cervical myelopathy (DCM) Dementia Dengue Depression Dermal scarring Dermatomyositis Developmental and Epileptic Encephalopathies (DEE) Diabetes Diabetic Foot Ulcers Diabetic macular edema (DME) Diabetic nephropathy Diabetic neuropathy Diabetic Retinopathy Diarrhea Diffuse Large B-Cell Lymphoma (DLBCL) Dravet Syndrome Dry eye disease Duchenne Muscular Dystrophy Dyslipidemia Ebola Eczema Egg Allergy Endometrial cancer Endometriosis Eosinophilic esophagitis Eosinophilic Gastritis Eosinophilic Granulomatosis with Polyangiitis (EGPA) Epidermolysis Bullosa Epilepsy Epithelioid Sarcoma Epstein-Barr virus (EBV-PTLD) Erectile dysfunction Erythropoietic protoporphyria (EPP) Esophageal cancer Esophagogastric adenocarcinoma Essential hypertension Essential thrombocythemia Essential tremor Exocrine pancreatic insufficiency (EPI) Fabry disease Facioscapulohumeral muscular dystrophy (FSHD) Factor Xa Familial Adenomatous Polyposis (FAP) Familial amyloid polyneuropathy (FAP) Familial amyloidotic cardiomyopathy (FAC) Familial chylomicronemia syndrome (FCS) Familial partial lipodystrophy (FPL) Fanconi Anemia (FA) Fascioliasis Fatty Acid Oxidation Disorders (FAOD) Female Sexual Arousal Disorder (FSAD) Female sexual dysfunction (FSD) Fibrodysplasia ossificans progressiva (FOP) Fibromyalgia Focal segmental glomerulosclerosis (FSGS) Follicular Lymphoma Forehead lines Fragile X syndrome Frailty Friedreich's Ataxia (FA) Friedreich’s ataxia (FA) Frozen Shoulder syndrome Gastric cancer Gastroenteritis Gastroesophageal reflux disease (GERD) Gastrointestinal stromal tumors (GIST) Gastroparesis Gaucher disease Generalized anxiety disorder (GAD) Generalized pustular psoriasis Genital warts Geographic atrophy (GA) Gestational Trophoblastic Neoplasia (GTN) Giant cell arteritis (GCA) Glabellar lines Glaucoma Glioblastoma Multiforme (GBM) Glioma Glomerulopathies Glucocorticoid-induced osteoporosis (GIOP) Glut1 DS Glycogen Storage Disease GM2 gangliosidosis GNE Myopathy Gonorrhea Gout Graft versus host disease (GvHD) Growth hormone deficiency GSD1 Gynecomastia H. pylori Hair-related Head and Neck Cancer Headache Hearing loss Heart failure Heat stroke Hemochromatosis Hemophilia Hemophilia A Hemophilia B Hemorrhoids Hemostasis Hepatic porphyrias Hepatitis B Hepatitis C (HCV) Hepatitis delta virus (HDV) Hepatocellular carcinoma (HCC) Hepatorenal syndrome (HRS) Hereditary Angioedema (HAE) Hernia Herpes Heterozygous Familial Hypercholesterolemia (HeFH) Hidradenitis Suppurativa High Triglycerides Hip-related HIV Hodgkin lymphoma Homozygous familial hypercholesterolemia (HoFH) Hot flashes Human lipomas Human Papilloma Virus (HPV) Huntingtons disease Hutchinson-Gilford Progeria Syndrome (HGPS) Hyperammonemia Hypercholesterolemia Hypereosinophilic syndrome (HES) Hyperkalemia Hyperlipidemias Hyperoxaluria Hyperphosphatemia Hyperprolactinemia Hypertriglyceridaemia Hypertriglyceridemia Hypertrophic cardiomyopathy (HCM) Hyperuricemia Hypoactive sexual desire disorder (HSDD) Hypoglycemia Hypogonadism Hypoparathyroidism Hypotension Idiopathic Hypersomnia Idiopathic Polypoidal Choroidal Vasculopathy Idiopathic pulmonary fibrosis (IPF) IgA nephropathy IgG4-Related Disease Immune Thrombocytopenic Purpura (ITP) Incisional complications Indolent Systemic Mastocytosis Infantile spasms (IS) Infections - various Inflammatory bowel disease (IBD) Influenza Inherited Metabolic Disorders (IMD) Insomnia Intermittent claudication (IC) Invasive aspergillosis Invasive candidiasis Irritable bowel syndrome (IBS) Jaundice Jet Lag Disorder Kidney disease Knee arthroplasty Lactose intolerance Lambert-Easton Myasthenic Syndrome (LEMS) Leber's Congenital Amaurosis (LCA) Leber’s hereditary optic neuropathy (LHON) Lennox-Gastaut syndrome Leukemia Leukocyte Adhesion Deficiency-I (LAD-I) Levodopa-Induced Dyskinesia Lipodystrophy Liposarcoma Liver cancer Liver Cirrhosis Liver disease Liver fibrosis Low Cardiac Output Syndrome Lung cancer Lung transplant rejection Lupus Lymphedema Lymphoma Macular Edema Malaria Malignant hyperthermia Malignant pleural disease Mantle cell lymphoma (MCL) Marginal zone lymphoma Medullary thyroid cancer Melanoma Ménière's disease Menkes disease Merkel cell carcinoma MERS virus (Middle East Respiratory Syndrome) Mesothelioma Metachromatic leukodystrophy (MLD) Methylmalonic Acidemia (MMA) Microsatellite Instability-High Cancer Migraine Mitochondrial Myopathy Molluscum Contagiosum Molybdenum cofactor deficiency (MoCD) MPS 7 MPS I MPS II MPS IIIA MPS IIIB MPS IVA Mucocutaneous candidiasis Multiple myeloma Multiple Osteochondroma (MO) Multiple Sclerosis (MS) Multiple system atrophy (MSA) Myasthenia Gravis (MG) Mycosis Fungoides Mydriasis Myelodysplastic syndromes (MDS) Myelofibrosis Myocardial ischemia Myopia Narcolepsy Nasal polyps Nasopharyngeal carcinoma (NPC) Neuroblastoma Neuroendocrine tumors Neurogenic Orthostatic Hypotension (nOH) Neuromyelitis Optica Spectrum Disorder (NMOSD) Neuropathic pain Neutropenia Nicotine Addiction Niemann-Pick Disease Non-cystic fibrosis bronchiectasis (non-CF BE) Non-Hodgkin Lymphoma (NHL) Non-infectious uveitis Non-small cell lung cancer (NSCLC) Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Nonproliferative Diabetic Retinopathy Nontuberculous mycobacteria (NTM) Norovirus Obesity Obsessive compulsive disorder (OCD) Obstructive Sleep Apnea (OSA) Ocular Inflammation Oculopharyngeal Muscular Dystrophy Oncology Opioid dependence Opioid overdose Opioid-induced constipation (OIC) Oral Mucositis Ornithine Transcarbamylase (OTC) Deficiency Osteoarthritis Osteoporosis Other Otitis media Ovarian cancer Overactive Bladder (OAB) Pain Painful Lumbosacral Radiculopathy (PLSR) Pancreatic cancer Papulopustular Rosacea Parkinson’s disease Paroxysmal Nocturnal Hemoglobinuria (PNH) Peanut Allergy Pemphigus vulgaris (PV) Pericarditis Peripheral artery disease Peripheral Neuropathic Pain (PNP) Phenylketonuria (PKU) Pheochromocytoma Phosphoglucomutase 1 (PGM1) deficiency Pigmented Villonodular Synovitis (PVNS) PKAN Plantar fasciitis Plaque psoriasis Plasma Plasminogen Deficiency Platelets Pneumonia Polycythemia Vera Pompe Disease Portal Hypertension Post-Bariatric Hypoglycemia (PBH) Post-herpetic neuralgia (PHN) Post-traumatic stress disorder (PTSD) Posterior Uveitis Postpartum depression (PPD) Prader-Willi Syndrome (PWS) Pre-term labor Preeclampsia Presbyopia Primary axillary hyperhidrosis Primary biliary cholangitis (PBC) Primary hyperoxaluria (PH) Primary Immune Deficiency Disease (PIDD) Primary immunodeficiency (PI) Primary ovarian insufficiency (POI) Primary palmar hyperhidrosis Primary sclerosing cholangitis (PSC) Progeria Progressive familial intrahepatic cholestasis (PFIC) Progressive keratoconus Progressive supranuclear palsy (PSP) Proliferative vitreoretinopathy (PVR) Prophylaxis Prostate cancer Proteus Syndrome Prurigo nodularis Pruritus Pseudomonas aeruginosa Psoriasis Psoriatic arthritis Psychosis Pulmonary arterial hypertension (PAH) Pulmonary Hypertension Pulmonary sarcoidosis Pyoderma Gangraenosum (PG) Pyoderma Gangrenosum Pyruvate kinase deficiency Rare Bile Acid Synthesis Disorders Renal cancer Renal cell cancer (RCC) Respiratory syncytial virus (RSV) Retinal diseases Rett syndrome Rheumatoid Arthritis Richter's Transformation Rosacea RPE65-Deficiency S. aureus Sarcomas Schizophrenia Scleroderma Seborrheic keratosis (SK) Secondary hyperparathyroidism (SHPT) Secondary hypogonadism Seizures Severe aplastic anemia (SAA) Severe burns Sexual health (female) Sexual health (male) Sezary syndrome Shingles Short bowel syndrome Sickle disease Sinus related Sinusitis Sjögren-Larsson Syndrome (SLS) Small cell lung cancer (SCLC) Small lymphocytic lymphoma (SLL) Smallpox Smith-Magenis Syndrome Smoking cessation Social Anxiety Disorder (SAD) Soild tumors Solid tumors Spasticity Spinal muscular atrophy (SMA) Spinal muscular atrophy (SMA) Type 1 Spinal muscular atrophy (SMA) Type 2 Spinal muscular atrophy (SMA) Type 3 Spinal-related Spinocerebellar Ataxia Squamous Cell Carcinoma of the Head and Neck (SCCHN) Squamous cell lung cancer SRSE Staphylococcus aureus Status Epilepticus Stress related Stress urinary incontinence (SUI) Stroke Systemic mastocytosis (SM) Systemic Sclerosis T-cell lymphoma Tardive dyskinesia Testosterone related Thrombocytopenia Thrombotic microangiopathy (TMA) Thyroid cancer Thyroid Eye Disease (TED) Tinnitus Tourette syndrome Transfusion-dependent thalassemia (TDT) Transplant Transthyretin cardiomyopathy Trigeminal Neuralgia Tuberous Sclerosis Complex Tumor-induced osteomalacia (TIO) Type 1 diabetes Type 2 diabetes Ulcerative Colitis Urea Cycle Disorder Urinary tract infections Urothelial cancer Usher Syndrome Uterine Fibroids Vascular Ehlers-Danlos Syndrome Vasculitis Vasomotor symptoms (VMS) Veno-occlusive Disease (VOD) Venous Leg Ulcers Venous Thromboembolism (VTE) Vertigo Vitiligo Vulvovaginal candidiasis (VVC) Waldenström’s macroglobulinemia Walnut Allergy Warm autoimmune hemolytic anemia (WAIHA) Warts Wet age-related macular degeneration (AMD) WHIM syndrome Wilson disease Women's health (pain/contraception) Wounds Wrinkles X-linked chronic granulomatous disease (X-CGD) X-Linked Hypophosphatemia (XLH) X-Linked Myotubular Myopathy X-linked Retinitis Pigmentosa (XLRP) X-linked retinoschisis (XLRS) Xerostomia Zika

Market Cap

Any Mega ($200bln and more) Large ($10bln to $200bln) Mid ($2bln to $10bln) Small ($300mln to $2bln) Micro ($50mln to $300mln) Nano (under $50mln) +Large (over $10bln) +Mid (over $2bln) +Small (over $300mln) +Micro (over $50mln) -Large (under $200bln) -Mid (under $10bln) -Small (under $2bln) -Micro (under $300mln)

Price

Any Under $1 Under $2 Under $3 Under $4 Under $5 Under $7 Under $10 Under $15 Under $20 Under $30 Under $40 Under $50 Over $1 Over $2 Over $3 Over $4 Over $5 Over $7 Over $10 Over $15 Over $20 Over $30 Over $40 Over $50 Over $60 Over $70 Over $80 Over $90 Over $100 $1 to $5 $1 to $10 $1 to $20 $5 to $10 $5 to $20 $5 to $50 $10 to $20 $10 to $50 $20 to $50 $50 to $100

Short ratio

Any Low (<5 days) High (>20 days) Under 5 days Under 10 days Under 15 days Under 20 days Under 25 days Under 30 days Over 5 days Over 10 days Over 15 days Over 20 days Over 25 days Over 30 days

Relative Volume

Any Over 10 Over 5 Over 3 Over 2 Over 1.5 Over 1 Over 0.75 Over 0.5 Over 0.25 Under 2 Under 1.5 Under 1 Under 0.75 Under 0.5 Under 0.25 Under 0.1

Price to book

Any Low (<3) High (>50) Under 1 Under 2 Under 3 Under 4 Under 5 Under 6 Under 7 Under 8 Under 9 Under 10 Over 1 Over 2 Over 3 Over 4 Over 5 Over 6 Over 7 Over 8 Over 9 Over 10 Over 20 Over 30 Over 40 Over 50

Apply Filters Reset Filters

Company

Price

Change

No of Shares

Market Cap

Short Ratio

Volume

Avg Daily Volume

Relative Volume

Price to Book

Open

Prev Close

EST EPCD

Updated

ABBV AbbVie Inc.

$79.25

-0.51  -0.64%

1.5 billion

$116.9 billion

3.18

2.6 million

6.9 million

0.38

-$13.83

$79.50

$79.76

03/25/2019

Tap to view 39 drug drugs

Drug	Indication	Stage	News
Risankizumab	Ulcerative colitis	Phase 3	Phase 3 trial to be initiated 1H 2018.
ABT-414	Recurrent glioblastoma (rGBM)	Phase 1	Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
Veliparib	Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)	Phase 3	Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib	Relapsed or refractory MCL mantle cell lymphoma	Approved	Approved November 13, 2013.
Imbruvica	Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy	Approved	Approved February 12, 2014.
Imbruvica	Deletion 17p	Approved	Approved July 19, 2014.
VIEKIRA PAK	HCV - genotype 1	Approved	Approved December 19, 2014.
IMBRUVICA	Waldenström’s Macroglobulinemia	Approved	Approved January 29, 2015 - PCYC
ABBV-8E12	Progressive supranuclear palsy (PSP)	Phase 2	Phase 2 initiation announced January 25, 2017.
ABBV-8E12	Alzheimer's disease	Phase 2	Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO)	Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)	Approved	Approval announced June 11, 2018.
Venetoclax	Relapsed or refractory multiple myeloma	Phase 3	Partial clinical hold announced March 19, 2019.
Venclexta	First-line Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial planned.
Venclexta	Follicular lymphoma (FL)	Phase 3	Phase 3 trial planned.
Risankizumab	Crohn’s Disease	Phase 3	Phase 3 trial to commence 2H 2017.
Risankizumab	Psoriasis	PDUFA	BLA filing announced April 25, 2018. PDUFA estimate April 24, 2019.
Imbruvica	Second-line Chronic graft-versus-host disease (GVHD)	Approved	Approval announced August 2, 2017.
ABT-494	Psoriatic Arthritis	Phase 3	Phase 3 trial to commenced 2017.
Risankizumab	Psoriatic Arthritis	Phase 2b	Phase 3 trial planned for 2018.
ABT-494	Crohn’s Disease	Phase 3	Phase 3 trial initiated late 2017.
Rova-T (TRINITY)	Third-line Small Cell Lung Cancer	Phase 2	Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494	Atopic Dermatitis	Phase 3	Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica	Marginal zone lymphoma	Approved	sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P)	Hepatitis C virus (HCV)	Approved	Approval announced August 3, 2017.
Elagolix	Uterine Fibroids	NDA Filing	NDA filing due 2019.
Elagolix	Endometriosis	Approved	FDA approval announced July 24, 2018.
ABT-494 upadacitinib	Rheumatoid arthritis	PDUFA priority review	PDUFA date under priority review estimated at August 19, 2019.
Rova-T (TAHOE)	Second-line Small Cell Lung Cancer	Phase 3	Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU)	First-line Small Cell Lung Cancer	Phase 3	Phase 3 data due 2020.
Imbruvica and Gazyva - iLLUMINATE	Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)	Approved	FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib)	Waldenström’s Macroglobulinemia	Approved	FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)	Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta	First line unfit AML	Approved	FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE	Ulcerative colitis	Phase 2/3	Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab	Chronic Lymphocytic Leukemia	sNDA Filing	sNDA filing announced March 7, 2018.
Ibrutinib (Imbruvica)	Pancreatic cancer	Phase 3	Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva	Chronic lymphocytic leukemia (CLL)	Phase 3	Phase 3 data due 2019.
Venclexta MIRROS	Acute myeloid leukemia (AML)	Phase 3	Phase 3 data due 2019.
Venclexta BELLINI	Multiple myeloma	Phase 3	Phase 3 data due 2019.

ABEO Abeona Therapeutics Inc.

$7.49

-0.03  -0.40%

47.9 million

$359.1 million

158.7 thousand

395.6 thousand

0.4

$2.67

$7.54

$7.52

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ABO-101	Sanfilippo syndrome type B (MPS IIIB)	Phase 1/2	Phase 1/2 ongoing as of December 6, 2018.
EB-101	Recessive dystrophic epidermolysis bullosa (RDEB)	Phase 1/2	Phase 3 trial to be initiated mid-2019.
ABO-102	Sanfilippo syndrome type A (MPS IIIA)	Phase 1/2	Phase 1/2 safety and tolerability data to be presented at WORLDSymposium February 6, 2019.

ABIO ARCA biopharma Inc.

$0.39

  +-0.77%

18.4 million

$7.1 million

127.9 thousand

1.2 million

0.11

$1.17

$0.38

$0.39

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Gencaro	Chronic Heart Failure	Phase 2b	Phase 3 trial to be initiated 4Q 2019 under SPA subject to securing additional financing.

ABUS Arbutus Biopharma Corporation

$3.57

+0.04  +1.13%

57.3 million

$204.5 million

126.6 thousand

168 thousand

0.75

$2.77

$3.54

$3.53

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ARB-1467, tenofovir, and pegylated interferon	Hepatitis B (HBV)	Phase 2	Phase 2 trial ongoing but no plans to continue further development.
ARB-1467	Hepatitis B (HBV)	Phase 2	Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
AB-452	Hepatitis B	Phase 1	Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due 3Q 2019.
AB-506	Hepatitis B (HBV)	Phase 1	Phase 1 data due late-2Q 2019.
AB-729	Hepatitis B (HBV)	Phase 1	Phase 1 trial to be initiated 2Q 2019.

ACAD ACADIA Pharmaceuticals Inc.

$26.16

+0.06  +0.23%

143.9 million

$3.8 billion

636.2 thousand

1.6 million

0.4

$7.86

$26.04

$26.10

03/25/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Pimavanserin	Adjunctive Treatment in Patients With Major Depressive Disorder	Phase 3	Phase 3 trial to be initiated 1H 2019.
Pimavanserin - Advance	Adjunctive treatment in patients with negative symptoms of schizophrenia	Phase 2	Phase 2 initiated November 2016. Enrolment to be completed 2H 2019.
Pimavanserin - Enhance	Adjunctive treatment of schizophrenia	Phase 3	Phase 3 data due mid-2019.
Pimavanserin - SERENE	Alzheimer’s disease agitation	Phase 2	Announced October 4, 2017 that trial will be discontinued.
Pimavanserin	Parkinson’s disease psychosis (PDP)	Approved	Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony	Alzheimer’s disease psychosis	Phase 3	Phase 3 interim data 2H 2019.
Trofinetide	Rett Syndrome	Phase 3	Phase 3 trial to be initiated 2H 2019.

ACER Acer Therapeutics Inc.

$22.96

+0.06  +0.26%

10.1 million

$231.6 million

20.5 thousand

28.8 thousand

0.71

$5.14

$22.93

$22.90

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
EDSIVO	Vascular Ehlers-Danlos Syndrome	PDUFA priority review	PDUFA date under priority review June 25, 2019.
Tovaxin (Tcelna)	Secondary Progressive MS (SPMS)	Phase 2b	Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001	Urea cycle disorder (UCD)	Phase 2	NDA filing planned for 2019.

ACHN Achillion Pharmaceuticals Inc.

$2.90

-0.03  -0.85%

138.7 million

$403 million

846.4 thousand

1.8 million

0.47

$1.51

$2.95

$2.93

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	End of Phase 2 meeting 4Q 2019.
JNJ-4178	Hepatitis C (HCV)	Phase 2a	Janssen noted September 11, 2017 that no further development planned.
ACH-4471	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 2	Phase 2 interim data due 2Q 2019.
JNJ-4178 - OMEGA-1	Hepatitis C (HCV)	Phase 2b	Janssen noted September 11, 2017 that no further development planned.
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	End of Phase 2 meeting 4Q 2019.
ACH-5228	Healthy volunteers	Phase 1	Phase 1 multiple ascending dose trial initiation announced January 31, 2019. To be completed 3Q 2019.

ACHV Achieve Life Sciences Inc.

$2.93

+0.1  +3.53%

6.7 million

$19.7 million

152.2 thousand

2 million

0.07

$1.25

$2.86

$2.83

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Cytisine	Smoking cessation	Phase 2b	Phase 2b data due mid-2019.

ACIU AC Immune SA

$5.05

+0.29  +6.09%

67.6 million

$341.2 million

246.3 thousand

731.9 thousand

0.34

$1.91

$4.76

$4.76

03/25/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Crenezumab - CREAD 2	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705)	Alzheimer’s disease	Phase 1b	Phase 2 data due 2020.
ACI-24 (anti-Abeta vaccine)	Alzheimer's disease-like characteristics in individuals with Down syndrome	Phase 1/2	Phase 1/2 interim high dose cohort data due 1H 2019, low dose cohort data due 2019.
Crenezumab - CREAD 1	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
ACI-24	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced August 20, 2018.
MTAU9937A	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced February 20, 2019.
ACI-35	Alzheimer’s disease	Phase 1b	Phase 2 trial planned for 1H 2019.

ACOR Acorda Therapeutics Inc.

$13.06

-0.07  -0.50%

47.6 million

$622.3 million

331.5 thousand

911.4 thousand

0.36

$1.02

$13.08

$13.13

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Ampyra	Improve walking in patients with multiple sclerosis		Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-427	Migraine	Phase 1	Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Tozadenant	Parkinson’s disease (PD)	Phase 3	Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine	Post stroke deficits	Phase 3	Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301)	OFF episodes of Parkinson’s disease (PD)	Approved	FDA Approval announced December 22, 2018.
BTT1023	Primary Sclerosing Cholangitis	Phase 2	Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.

ACRS Aclaris Therapeutics Inc.

$5.95

-0.17  -2.78%

41.3 million

$245.6 million

431.2 thousand

529.5 thousand

0.81

$1.14

$6.09

$6.12

03/25/2019

Tap to view 9 drug drugs

Drug	Indication	Stage	News
ATI-502 (ATI-50002-AA-201) - dose ranging	Alopecia areata	Phase 2	Phase 2 data due 2Q 2019.
ATI-502 (VITI-201 Topical)	Vitiligo	Phase 2	Phase 2 open label 6-month data due 2Q 2019.
ATI-502 AUATB-201 - open label	Alopecia areata - regrowth of eyebrows	Phase 2	Phase 2 trial ongoing.
ATI-501 (AUAT-201 Oral)	Alopecia areata	Phase 2	Phase 2 data due 2H 2019.
ESKATA (hydrogen peroxide)	Seborrheic keratosis (SK)	Approved	Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2	Common warts (verruca vulgaris)	Phase 3	Phase 3 data due 2H 2019.
ATI-502 AA-202 Topical - PK/safety	Alopecia areata	Phase 2	Phase 2 interim data released June 28, 2018.
ATI-502 (ATI-50002-AGA-201) - open label	Androgenetic alopecia (AGA) - Hair loss	Phase 2	Phase 2 data due 2H 2019.
ATI-502 (AD-201 Topical)	Atopic dermatitis (AD)	Phase 2	Phase 2 data due mid-2019.

ACRX AcelRx Pharmaceuticals Inc.

$3.21

+0.05  +1.58%

78.8 million

$252.8 million

1.3 million

2.4 million

0.53

$64.20

$3.21

$3.16

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ARX-04 (SAP302)	Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury	Phase 3	Phase 3 data released August 15 2016
DSUVIA (ARX-04)	Moderate-to-severe acute pain following a surgical procedure	Approved	FDA Approval announced November 2, 2018.
Zalviso	Post-operative pain following open abdominal surgery and hip or knee replacement surgery	Phase 3	CRL Jul 26 2014. NDA resubmission timing being evaluated.

ACST Acasti Pharma Inc.

$1.02

-0.03  -2.86%

78.1 million

$79.7 million

182.3 thousand

328.3 thousand

0.56

$3.52

$1.03

$1.05

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
CaPre (TRILOGY trial)	Hypertriglyceridemia	Phase 3	Phase 3 top-line data due by the end of 2019.

ADAP Adaptimmune Therapeutics plc

$3.77

+0.14  +3.86%

104.7 million

$394.8 million

172.7 thousand

262.5 thousand

0.66

$1.60

$3.61

$3.63

03/25/2019

Tap to view 8 drug drugs

Drug	Indication	Stage	News
NY-ESO T-cell therapy	Synovial sarcoma - cancer	Phase 1/2	Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy	Ovarian cancer	Phase 1/2	Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy	Myxoid round cell liposarcoma (MRCLS)	Phase 1/2	Phase 1/2 presentation at SITC November 2018.
NY-ESO T-cell therapy	Myeloma	Phase 1/2	Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 initiated November 2015. Data are due 2017.
MAGE-A4	Soild tumors	Phase 1	Updated data on trials for solid tumors due 1Q earnings call - estimate May 9, 2019.
AFP	Hepatocellular carcinoma	Phase 1	Dose escalation to Cohort 2 in early 2019.
MAGE-A10	Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Phase 1 data at ESMO noted no current response.

ADIL Adial Pharmaceuticals Inc

$2.96

-0.05  -1.81%

10.1 million

$29.8 million

43.7 thousand

576.1 thousand

0.08

$6.72

$2.99

$3.01

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AD04	Alcohol use disorder	Phase 3	Phase 3 European trial planned 1H 2019.

ADMA ADMA Biologics Inc

$3.20

-0.11  -3.32%

46.4 million

$148.3 million

658 thousand

521.7 thousand

1.26

$7.44

$3.35

$3.31

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
RI-002	Primary Immune Deficiency Diseases	PDUFA	CRL issued July 29 2016. New PDUFA date April 2, 2019.
BIVIGAM	Primary humoral immunodeficiency	CRL	Response to Complete Response Letter submitted January 7, 2019.

ADMP Adamis Pharmaceuticals Corporation

$2.10

-0.04  -1.87%

47.3 million

$99.3 million

714 thousand

416.7 thousand

1.71

$2.12

$2.11

$2.14

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Epinephrine Pre-filled Syringe (PFS)	Emergency treatment of anaphylaxis.	Approved	CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000	Asthma/COPD	Phase 2	Phase 3 planned for December 2018.
Symjepi - low dose	Anaphylaxis	Approved	FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection	Opioid overdose	PDUFA	PDUFA date October 31, 2019.
APC-8000 (sublingual tadalafil)	Erectile dysfunction	NDA Filing	Refusal to file letter received February 26, 2019.

ADMS Adamas Pharmaceuticals Inc.

$7.40

-0.26  -3.39%

27.4 million

$203.1 million

189.8 thousand

619.5 thousand

0.31

$2.26

$7.65

$7.66

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ADS-4101	Partial onset seizures in patents with epilepsy	Phase 1b	Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
GOCOVRI (amantadine)	Multiple sclerosis (MS)	Phase 3	Phase 3 data due 2H 2019.
Namzaric	Moderate to severe dementia of the Alzheimer's type.	Approved	Approved December, 24 2014.
ADS-5102	Levodopa-Induced Dyskinesia	Approved	Approval announced August 24, 2017.
GOCOVRI (amantadine)	Dyskinesia patients with Parkinson's disease	Phase 3	Phase 3 open-label data released April 19, 2018.

ADRO Aduro Biotech Inc.

$3.75

+0.08  +2.18%

79.7 million

$298.9 million

336.3 thousand

616.8 thousand

0.55

$2.21

$3.66

$3.67

03/25/2019

Tap to view 10 drug drugs

Drug	Indication	Stage	News
BION-1301	Multiple Myeloma	Phase 1/2	Phase 1/2 poster at AACR Apr 1, 2019 1pm.
ADU-S100	Solid tumors or lymphomas	Phase 1b	Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
CRS-207 and GVAX Pancreas - ECLIPSE trial	Pancreatic cancer	Phase 2b	Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial	Pancreatic cancer	Phase 2b	Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab	Mesothelioma - cancer	Phase 2	Noted December 12, 2017 that development to be discontinued.
pLADD	Colorectal Cancer	Phase 1	Phase 1 ongoing.
pLADD	Colorectal Cancer	Phase 1	Phase 1 ongoing.
ADU-214 with Nivolumab	Non-Small Cell Lung Cancer	Phase 1/2	Phase 1b initiation announced June 7, 2018.
ADU-S100 and Spartalizumab	Solid tumors or lymphomas	Phase 1b	Phase 1 dose escalation data due 2H 2019.
ADU-S100 and ipilimumab	Melanoma	Phase 1	Phase 1 commencement of dosing announced February 11, 2019.

ADVM Adverum Biotechnologies Inc.

$5.41

-0.1  -1.81%

63.2 million

$341.9 million

197.7 thousand

409.2 thousand

0.48

$1.70

$5.47

$5.51

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ADVM-043	Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/2	Development to be discontinued - noted November 1, 2018.
AVA-101	Wet age-related macular degeneration (Wet-AMD)	Phase 2a	Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022	Wet age-related macular degeneration (Wet-AMD)	Phase 1	Phase 1 Interim data due 1Q 2020.

ADXS Advaxis Inc.

$0.49

+0.01  +2.19%

82.6 million

$40.5 million

4 million

1.3 million

3.11

$1.09

$0.50

$0.48

03/25/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Axalimogene filolisbac + durvalumab	Recurrent or refractory HPV-associated cervical cancer and head & neck cancer	Phase 1/2	Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046	Castrate-resistant prostate cancer	Phase 1/2	Phase 1 safety and immunogenicity data to be presented at AACR April 1, 2019 1:00 p.m.
Axalimogene filolisbac - AIM2CERV Trial	High-risk, locally advanced cervical cancer	Phase 3	Phase 3 partial clinical hold announced January 23, 2019. No new enrolments permitted until hold released.
ADXS-HER2	HER2-driven malignancies - cancer	Phase 1b	Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac	Anal cancer (FAWCETT)	Phase 2	Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO	Non-small cell lung cancer (NSCLC)	Phase 1	Phase 1 safety and immunogenicity data to be presented at AACR March 31, 2019 1:00 p.m.
ADXS-HOT 503	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 safety, tolerability and immune correlative data due by the end of June 2019.

AERI Aerie Pharmaceuticals Inc.

$45.60

-1.22  -2.61%

45.9 million

$2.1 billion

249.1 thousand

726 thousand

0.34

$9.19

$46.68

$46.82

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Roclatan	Glaucoma	Approved	FDA Approval announced March 12, 2019.
Rhopressa	Glaucoma	Approved	PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.

AEZS Aeterna Zentaris Inc.

$4.17

+0.03  +0.72%

16.4 million

$68.6 million

157.2 thousand

338.3 thousand

0.46

$9.27

$4.13

$4.14

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Macimorelin Acetate - Macrilen	Adult Growth Deficiency	Approved	CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex	Endometrial cancer	Phase 3	Phase 3 trial did not meet primary endpoint - May 1, 2017.

AFMD Affimed N.V.

$4.01

+0.01  +0.25%

62.4 million

$250.3 million

505.4 thousand

561.1 thousand

0.9

$6.17

$3.99

$4.00

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AFM13 with Keytruda	Hodgkin Lymphoma - Cancer	Phase 1b	Phase 1b data at ASH noted 46% CR; 88% ORR.
AFM13	Hodgkin Lymphoma - Cancer	Phase 2	Phase 2a ongoing.
AFM13	CD30-positive lymphoma	Phase 1/2	Phase 1b/2a data at ASH 2018 noted 4/9 ORs including 1CR.
AFM11	Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)	Phase 1	Phase 1 trial placed on clinical hold - October 8, 2018.
AFM13	Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF)	Phase 2	Phase 2 trial to be initiated 1H 2019.

AGEN Agenus Inc.

$2.81

-0.01  -0.53%

134.2 million

$376.4 million

358.9 thousand

1.6 million

0.22

-$2.17

$2.82

$2.82

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AGEN2034 and AGEN1884	Solid tumors	Phase 1/2	Phase 1/2 enrolment to be completed 2019.
AGEN1884 (anti-CTLA-4)	Solid cancers	Phase 1	Phase 1 presentation at ASCO 2018. 31% ORR.
Shingrix	Shingles	Approved	Approval announced October 20, 2017.
AGEN2034 (anti-PD-1)	Cervical cancer	Phase 1/2	Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
INCAGN1949	Solid tumors - cancer	Phase 1/2	Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1876	Solid tumors - cancer	Phase 1/2	Phase 1/2 trial commenced June 2016

AGIO Agios Pharmaceuticals Inc.

$62.10

-0.19  -0.31%

58.4 million

$3.6 billion

149.5 thousand

468.9 thousand

0.32

$5.28

$62.15

$62.29

03/25/2019

Tap to view 14 drug drugs

Drug	Indication	Stage	News
AG-348 - Mitapivat	Thalassemia	Phase 2	Phase 2 data due 2H 2019.
Ivosidenib	IDH1m Relapsed/Refractory AML - cancer	Approved	FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE)	Pyruvate kinase deficiency	Phase 3	Phase 3 enrolment to be completed 2019.
AG-120 and VIDAZA - AGILE	Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer	Phase 3	Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY	Refractory Acute myeloid leukemia (AML) - cancer	Phase 3	Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221	Advanced hematologic malignancies with an IDH2 mutation	Approved	Approval announced August 1, 2017.
AG-120 Ivosidenib	IDH1 mutant positive cholangiocarcinoma - cancer	Phase 3	Phase 3 top-line data due 1H 2019.
AG-120 Ivosidenib	R/R Acute Myeloid Leukemia (AML)	Phase 1	Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA	Frontline AML with IDH1 or IDH2 mutation	Phase 1/2	Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib	Frontline AML with IDH1 or IDH2 mutation	Phase 1	Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270	Solid tumors	Phase 1	Phase 1 dose escalation data due 1H 2019.
Vorasidenib (AG-881)	Glioma	Phase 3	Phase 3 trial to be initiated YE 2019.
Ivosidenib	Frontline AML with IDH1 mutation	PDUFA priority review	PDUFA date under priority review June 21, 2019.
Ivosidenib and Vorasidenib (AG-881)	IDHm low-grade glioma	Phase 1	Phase 1 data due 1H 2019.

AGLE Aeglea BioTherapeutics Inc.

$7.88

+0.14  +1.74%

28.8 million

$227.2 million

60.3 thousand

182.6 thousand

0.33

$3.37

$7.54

$7.75

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AEB1102	Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)	Phase 1	Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102)	Arginase I deficiency	Phase 1/2	Phase 1/2 data to be presented at SIMD April 6-9, 2019. Phase 3 trial to be initiated 2Q 2019 with data due 1Q 2021.
AEB1102	Solid tumors	Phase 1	Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102)	Solid tumors	Phase 1	Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA	Small cell lung cancer (SCLC)	Phase 2	Phase 2 top-line open label data due 1H 2020.

AGN Allergan plc

$146.78

-2.52  -1.69%

332.6 million

$48.8 billion

1.08

1.4 million

2.9 million

0.49

$0.75

$148.88

$149.30

03/25/2019

Tap to view 29 drug drugs

Drug	Indication	Stage	News
Botox	Forehead lines	Approved	Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX	Overactive Bladder (OAB)	Phase 2	Phase 2 data due 2019.
JUVÉDERM VOLLURE	Correction of moderate to severe facial wrinkles and folds	Approved	Approval announced March 20, 2017.
Brazikumab	Crohn's disease	Phase 3	Phase 3 to be initiated 2H 2018 with data due 2020.
Bimatoprost	Androgenic Alopecia	Phase 3	Phase 3 enrollment to be completed 2H 2018.
Botox	Depression	Phase 2	Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist	Psoriasis	Phase 2b	Phase 2b trial ongoing.
Cariprazine	Maintenance Treatment of Schizophrenia	Approved	Approval announced November 13, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	Phase 3 Non-Hodgkin’s lymphoma expected 2019.
ATOGEPANT	Prophylaxis (migraine)	Phase 2b	Phase 3 trial to be initiated 1H 2019 with data due in 2020.
RAPASTINEL	Major depressive disorder (MDD)	Phase 3	Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN	Diabetic Gastroparesis	Phase 3	Phase 3 initiated 2H 2017 with top-line data due 2020.
ESMYA (ulipristal acetate)	Uterine Fibroids	CRL	CRL issued August 21, 2018.
ABICIPAR	Diabetic macular edema (DME)	Phase 3	Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC)	Nonalcoholic steatohepatitis (NASH)	Phase 3	Phase 3 data due 2020.
ABICIPAR	Age-related macular degeneration (AMD)	Phase 3	Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI)	Approved	sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0%	Facial Erythema (Redness) Associated with Rosacea	Approved	Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults	Chronic idiopathic constipation (CIC)	Approved	sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	Approved	Approved September 14, 2017.
Sarecycline	Severe acne vulgaris	Approved	FDA Approval announced October 2, 2018.
Cariprazine	Bipolar I Depression	PDUFA	PDUFA date for sNDA filing May 2019.
UBROGEPANT	Migraine	PDUFA	NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
Brazikumab	Ulcerative colitis	Phase 2/3	Phase 2/3 data due 2020.
Brimo DDS	Geographic atrophy	Phase 3	Phase 3 trial to be initiated 2H 2018.
Bimatoprost	Open-angle glaucoma or ocular hypertension	NDA Filing	NDA filing due 2H 2019.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI) - pediatric	Approved	FDA Approval announced March 18, 2019.
Botox	Lower limb spasticity	PDUFA	PDUFA date 4Q 2019.
Botox	Upper limb spasticity	PDUFA priority review	PDUFA date under priority review 2Q 2019. Exact date not provided.

AGRX Agile Therapeutics Inc.

$1.54

+0.06  +4.05%

43.2 million

$66.5 million

177.1 thousand

645.9 thousand

0.27

$3.28

$1.47

$1.48

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Twirla	Contraceptive patch	NDA Filing	CRL issued 2013. Further CRL issued December 22, 2017. Resubmission due 2Q 2019.

AGTC Applied Genetic Technologies Corporation

$4.34

+0.17  +4.08%

18.2 million

$78.8 million

16.1 thousand

100.8 thousand

0.16

$1.04

$4.15

$4.17

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AAV Gene Therapy	CNGB3 Achromatopsia	Phase 1/2	Phase 1/2 data due 1H 2020.
rAAV-hRS1	X-linked retinoschisis (XLRS)	Phase 1/2	Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AAV-based gene therapy	X-linked Retinitis Pigmentosa (XLRP)	Phase 1/2	Phase 1/2 dose escalation data due 3Q 2019. Expansion data due 4Q 2019.

AIMT Aimmune Therapeutics Inc.

$22.23

+0.76  +3.51%

62.2 million

$1.4 billion

426.9 thousand

655.9 thousand

0.65

$4.62

$22.33

$21.48

03/25/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
AR101 ARTEMIS	Peanut Allergy	Phase 3	Phase 3 enrollment has commenced - noted June 5, 2017. Data due 1H 2019.
AR101 RAMSES	Peanut Allergy	Phase 3	Phase 3 data released November 8, 2018 noted no serious adverse events
AR101	Peanut Allergy	BLA Filing	BLA filing announced December 21, 2018. BLA filing acceptance expected by end of March 2019 (delay due to govt shutdown).
AR 201	Egg Allergy	Phase 2	Phase 2 trial to be initiated mid-2019.
AR 301	Walnut Allergy	Phase 2	Phase 2 trial to be initiated 2H 2019.
AR101 with adjunctive dupilumab	Peanut Allergy	Phase 2	Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON	Peanut Allergy	Phase 3	Phase 3 initiation announced December 19, 2018.

AKAO Achaogen Inc.

$0.51

-0.01  -1.73%

63.2 million

$32.3 million

837.6 thousand

1.6 million

0.51

$1.31

$0.52

$0.52

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
C-Scape	Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens	Phase 3	Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
Plazomicin	Complicated urinary tract infections (cUTI)	Approved	FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin - CARE	Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)	Phase 3	Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.

AKBA Akebia Therapeutics Inc.

$8.54

+0.15  +1.79%

116.9 million

$998.2 million

413.6 thousand

1.1 million

0.38

$7.00

$8.37

$8.39

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Vadadustat - TRILO2GY	Three-times-weekly dosing regimen for vadadustat	Phase 3	Phase 3 trial to be initiated in 2019, with top-line results expected in 2020.
Vadadustat - FO2RWARD	Renal anemia	Phase 2	Phase 2 trial data due 2019.
Auryxia	Hyperphosphatemia	Approved	Approved Sept 5, 2014.
Vadadustat - INNO2VATE	Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)	Phase 3	Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT	Non-dialysis patients with anemia related to CKD (NDD-CKD)	Phase 3	Phase 3 data due mid-2020.
Auryxia	Iron deficiency anemia in non-dialysis dependent CKD patients	Approved	sNDA FDA Approval announced November 7, 2017.

AKCA Akcea Therapeutics Inc.

$26.90

-0.95  -3.41%

89.4 million

$2.4 billion

97.9 thousand

261.1 thousand

0.38

$8.71

$28.64

$27.85

03/25/2019

Tap to view 9 drug drugs

Drug	Indication	Stage	News
AKCEA-ANGPTL3-LRx	Rare hyperlipidemias	Phase 2	Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx	Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus	Phase 2	Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx	Hyperlipoproteinemia and established cardiovascular disease	Phase 2b	Phase 2b data due 1H 2020.
AKCEA-APO(a)-LRx	Hyperlipoproteinemia(a) and established cardiovascular disease	Phase 2b	Phase 2 data presented at AHA November 2018 - endpoints met.
Inotersen (IONIS-TTRRx)	NEURO-TTR - familial amyloid polyneuropathy (FAP).	Approved	FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH	Familial chylomicronemia syndrome (FCS)	CRL	CRL issued August 27, 2018.
Volanesorsen	Partial lipodystrophy rapidly	Phase 3	Phase 3 initiated November 2015
Volanesorsen	Familial partial lipodystrophy (FPL)	Phase 3	Phase 3 data due mid-2019.
AKCEA-TTR-LRx	hATTR Amyloidosis	Phase 1/2	Phase 1/2 data and Phase 3 trial initiation due 2019.

AKTX Akari Therapeutics Plc

$3.87

-0.23  -5.62%

15.8 million

$61.2 million

264.4 thousand

2.4 million

0.11

$9.67

$4.06

$4.10

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Coversin - CAPSTONE	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 3	Phase 3 data due 2019.
Coversin	Atopic keratoconjunctivitis	Phase 1/2	Phase 1/2 data due 1Q 2019.
Coversin	Bullous Pemphigoid	Phase 2	Phase 2 data due 1Q 2019.
Coversin	Atypical hemolytic-uremic syndrome (aHUS)	Phase 2	Phase 2 data due 1H 2019.

ALBO Albireo Pharma Inc.

$28.67

+0.27  +0.95%

12 million

$344.8 million

12.2 thousand

35.4 thousand

0.34

$2.81

$28.40

$28.40

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
A4250 - PEDFIC- 1	Liver disease	Phase 3	Phase 3 top-line data due late 2019 or early 2020.
Elobixibat	Nonalcoholic steatohepatitis (NASH)	Phase 2	Phase 2 trial planned for 2Q 2019.
A4250	Biliary atresia	Phase 3	Phase 3 trial planned for 2H 2019.

ALDR Alder BioPharmaceuticals Inc.

$13.05

+0.1  +0.77%

68.5 million

$893.9 million

283.5 thousand

1.1 million

0.25

$8.11

$12.98

$12.95

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Eptinezumab ALD403	Frequent episodic migraine	BLA Filing	BLA filing announced February 22, 2019.
ALD403	Chronic Migraine	Phase 2b	Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1	Frequent episodic migraine	Phase 3	Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.

ALDX Aldeyra Therapeutics Inc.

$7.26

-0.19  -2.55%

27.4 million

$198.9 million

200.6 thousand

244 thousand

0.82

$2.30

$7.47

$7.45

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
ADX-102	Dry eye syndrome	Phase 2b	Phase 3 planned for 1H 2019.
Reproxalap (ADX-102)	Allergic conjunctivitis	Phase 3	Phase 3 data due early 2019.
ADX-102	Noninfectious anterior uveitis	Phase 3	Phase 3 data due 2H 2019.
ADX-102	Sjögren-Larsson Syndrome (SLS)	Phase 3	Phase 3 initial data due in 2H 2019.
ADX-1612 (ganetespib)	Mesothelioma	Phase 2	Phase 2 trial to be initiated in 2019.
ADX-2191	Proliferative vitreoretinopathy (PVR)	Phase 3	Phase 3 trial to be initiated 2H 2019 with initial data due 2020.

ALEC Alector Inc.

$19.24

+1.19  +6.58%

68.4 million

$1.3 billion

23.3 thousand

0

-$15.90

$18.16

$18.05

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
AL001	Frontotemporal Dementia	Phase 1	Phase 1b trial to be initiated 1H 2019.
AL002	Alzheimer’s disease	Phase 1	Phase 1 trial initiated 2H 2018.

ALIM Alimera Sciences Inc.

$1.09

+0.05  +4.81%

71 million

$77.4 million

116.4 thousand

107.9 thousand

1.08

-$2.79

$1.06

$1.04

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Iluvien	Diabetic macular edema	Approved	CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014

ALKS Alkermes plc

$33.31

-0.65  -1.91%

156 million

$5.2 billion

285 thousand

820.1 thousand

0.35

$4.43

$34.04

$33.96

03/25/2019

Tap to view 12 drug drugs

Drug	Indication	Stage	News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)	Schizophrenia	Approved	FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early	Schizophrenia - young adults	Phase 3	Phase 3 data due early 2020.
ALKS 3831 - ENLIGHTEN-2	Schizophrenia	NDA Filing	Phase 3 data released November 29, 2018 met co-primary endpoints. NDA filing due mid-2019.
BYDUREON	Type 2 diabetes	Approved	CRL received March 15, 2010.
Aristada	Schizophrenia	Approved	Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098)	Multiple sclerosis (MS)	PDUFA	NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
ALKS 6428	Opioid dependence	Phase 3	Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461	Major depressive disorder	CRL	CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1	Schizophrenia	Phase 3	Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230	Solid tumors	Phase 1	Phase 1 initial data at SITC November 9, 2018.
Aristada and Invega Sustenna	Schizophrenia	Phase 3	Phase 3 data due 1H 2019.
ALKS 4230 + Keytruda - ARTISTRY-2	Solid tumors	Phase 1	Phase 1 initiation announced February 26, 2019.

ALLK Allakos Inc.

$36.41

+0.11  +0.30%

43.1 million

$1.6 billion

229.5 thousand

425.9 thousand

0.54

$8.53

$36.31

$36.30

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AK002	Severe Allergic Conjunctivitis	Phase 1	Phase 1 data due 2Q 2019.
AK002	Indolent Systemic Mastocytosis	Phase 1	Phase 1 data released February 19, 2019.
AK002	Chronic Urticaria	Phase 2	Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002	Eosinophilic Gastritis	Phase 2	Phase 2 top-line data due mid-2019.

ALLO Allogene Therapeutics Inc.

$24.88

-0.67  -2.62%

121.5 million

$3 billion

521.5 thousand

414.3 thousand

1.26

$4.30

$25.69

$25.55

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
UCART19 (PALL)	Acute lymphoblastic leukemia (ALL)	Phase 1	Phase 1 update at ASH December 3, 2018 noted 86% CR/CRi.
UCART19 - CALM	Refractory B-cell Acute Lymphoblastic Leukaemia	Phase 1	Phase 1 update at ASH December 3, 2018 noted 57% CR/CRi.
ALLO-715	Multiple myeloma	Phase 1/2	Phase 1/2 trial to be initiated 1H 2019.
ALLO-501	Non-Hodgkin lymphoma (NHL)	Phase 1	Phase 1 trial to be initiated 1H 2019.

ALNA Allena Pharmaceuticals Inc.

$6.87

-0.1  -1.43%

20.8 million

$143 million

4.2 thousand

40.3 thousand

0.1

$2.89

$6.98

$6.97

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Reloxaliase ALLN-177 (URIROX-1)	Enteric Hyperoxaluria	Phase 3	Data from first Phase 3 trial due 2H 2019.
Reloxaliase ALLN-177 open label	Primary hyperoxaluria	Phase 2	Phase 2 interim data due 1H 2019 and top-line data due 2H 2019.

ALNY Alnylam Pharmaceuticals Inc.

$83.89

-0.62  -0.74%

106.3 million

$8.9 billion

306.8 thousand

822.1 thousand

0.37

$6.85

$84.27

$84.52

03/25/2019

Tap to view 12 drug drugs

Drug	Indication	Stage	News
Fitusiran	Hemophilia A and B	Phase 2	Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran	Acute hepatic porphyrias	Phase 3	Phase 3 data released March 6, 2019 met primary endpoint. SAEs double that of placebo. Rolling NDA has been initiated.
Inclisiran - ORION-9	Hypercholesterolemia	Phase 3	Phase 3 data 3Q 2019.
ALN-HBV02 (VIR-2218))	Chronic hepatitis B virus (HBV)	Phase 1/2	Phase 1/2 data due 2019.
Lumasiran (ALN-GO1) ILLUMINATE-A	Primary Hyperoxaluria Type 1 (PH1)	Phase 3	Phase 3 data due late-2019.
Patisiran	Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Approved	FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran)	IgA nephropathy	Phase 2	Phase 2 trial to be initiated.
Fitusiran (ATLAS)	Hemophilia	Phase 3	Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
ALN-TTRsc02 - HELIOS-A	ATTR amyloidosis	Phase 3	Phase 3 trial enrolling - noted December 6, 2018.
Inclisiran - ORION-10	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 sata due 3Q 2019.
Inclisiran - ORION 11	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 data due 3Q 2019.
ALN-AAT02	alpha-1 anti-trypsin deficiency-associated liver disease	Phase 1/2	Phase 1/2 data due 2019.

ALPN Alpine Immune Sciences Inc.

$6.94

+0.09  +1.31%

18.6 million

$128.8 million

3.3 thousand

16.2 thousand

0.2

$2.89

$6.80

$6.85

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
N91115	Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein	Phase 2	Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101	Healthy volunteers	Phase 1	Phase 1 safety trial initiation announced February 11, 2019.

ALRN Aileron Therapeutics Inc.

$1.87

-0.07  -3.61%

14.7 million

$27.6 million

34.5 thousand

376.8 thousand

0.09

$1.06

$1.94

$1.94

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ALRN-6924	Peripheral T-cell lymphoma (PTCL)	Phase 2a	Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C)	Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)	Phase 1b	Phase 1/1b interim data due 1H 2019 with final data 2H 2019.
ALRN-6924 and IBRANCE (palbociclib)	Solid tumors	Phase 1b	Phase 2a commencement of enrolment in expansion cohort announced January 16, 2019 with preliminary data due 2H 2019.
ALRN-6924 and Paclitaxel	Breast cancer	Phase 1	Phase 1 trial to be initiated 1H 2019 with initial data due 2H 2019.

ALT Altimmune Inc.

$2.84

  +-0.04%

9.1 million

$25.8 million

394 thousand

1.8 million

0.22

$0.65

$2.89

$2.84

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
HepTCell	Hepatitis B	Phase 1	Phase 1 trial met primary endpoint. Phase 2 planned.
NasoVAX	Flu vaccine	Phase 2	Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD	Anthrax	Phase 1	Phase 1 data showed limited response.

ALXN Alexion Pharmaceuticals Inc.

$131.07

+0.86  +0.66%

223.5 million

$29.3 billion

964.1 thousand

1.6 million

0.59

$3.20

$130.29

$130.21

03/25/2019

Tap to view 8 drug drugs

Drug	Indication	Stage	News
Eculizumab	Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	PDUFA priority review	PDUFA date under priority review June 28, 2019.
ALXN1210	atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3	Phase 3 data released January 28, 2019. Primary endpoint met. Regulatory filing due 1H 2019.
ULTOMIRIS (ravulizumab-cwvz)	Paroxysmal nocturnal hemoglobinuria (PNH)	Approved	FDA approval announced December 21, 2018.
Eculizumab	Refractory generalized myasthenia gravis (gMG)	Approved	Approval announced October 23, 2017.
WTX101	Wilson disease	Phase 3	Phase 3 trial is enrolling.
ULTOMIRIS (ravulizumab-cwvz)	Generalized myasthenia gravis (gMG)	Phase 3	Phase 3 trial to be initiated 1Q 2019.
ALXN1830	Warm autoimmune hemolytic anemia (WAIHA)	Phase 1/2	Phase 1b/2a trial to be completed in 2019 with two pivotal trials to follow.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous	Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3	Phase 3 PK data due early 2020.

AMAG AMAG Pharmaceuticals Inc.

$12.06

-0.1  -0.82%

34.7 million

$418.6 million

158.1 thousand

749.3 thousand

0.21

$0.56

$12.18

$12.16

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Digoxin immune fab (DIF)	Severe preeclampsia in pregnant women	Phase 2/3	Phase 2/3 top-line data due 1H 2020.
Vyleesi (Bremelanotide)	Female sexual dysfunction (FSD)	PDUFA	PDUFA date extended to June 23, 2019.
Feraheme	Adults with iron deficiency anemia (IDA)	Approved	Approval for sNDA filing announced February 5, 2018.
Makena - auto injector	Reduce the risk of preterm birth in women with a singleton pregnancy	Approved	Approval announced February 14, 2018.
Makena	Preterm birth	Phase 3	Phase 3b trial did not meet co-primary endpoints - March 8, 2019.

AMGN Amgen Inc.

$186.06

-0.64  -0.34%

622.3 million

$115.8 billion

1.4 million

3.1 million

0.46

$9.26

$186.64

$186.70

03/25/2019

Tap to view 26 drug drugs

Drug	Indication	Stage	News
Tezepelumab - NAVIGATOR	Asthma	Phase 3	Phase 3 data due 2020.
Prolia (denosumab)	Glucocorticoid-induced osteoporosis (GIOP)	Approved	Approval announced May 21, 2018.
KYPROLIS (ASPIRE)	Relapsed Multiple Myeloma	Approved	sNDA approval announced June 11, 2018.
Vectibix (Panitumumab)	Wild-Type RAS Metastatic Colorectal Cancer	Approved	sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	PDUFA	Approved September 14, 2017.
Corlanor	Chronic Heart Failure	Approved	Approved April 15, 2015.
Erenumab	Migraine	Approved	Approval announced May 17, 2018.
CNP 520	Alzheimer’s Disease	Phase 3	Phase 3 ongoing. Expected completion 2024.
Repatha	Cardiovascular disease	Approved	Approval announced December 1, 2017.
XGEVA	Multiple Myeloma	Approved	sBLA approval announced January 5, 2017.
KYPROLIS (ARROW)	Multiple Myeloma	Approved	FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR)	Relapsed Multiple Myeloma	Approved	sNDA approved January 17, 2018.
BLINCYTO	Ph+ R/R ALL	Approved	PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	Phase 3 Non-Hodgkin’s lymphoma expected 2019.
ABP 980	Herceptin biosimilar	CRL	CRL issued June 1, 2018.
ABP 710	REMICADE biosimilar - rheumatoid arthritis	BLA Filing	BLA filing announced December 17, 2018.
Parsabiv	Secondary hyperparathyroidism (SHPT)	Approved	Approved February 7, 2017.
EVENITY (Romosozumab)	Osteoporosis	PDUFA	CRL issued July 16, 2017. BLA filing resubmission announced July 13, 2018. Advisory committee meeting January 16, 2019 voted 18-1 in favor of approval.
Omecamtiv mecarbil GALACTIC-HF	Acute heart failure	Phase 3	Phase 3 interim analysis March 20, 2019 noted trial to continue as planned. Enrolment to be completed 1H 2019.
Omecamtiv mecarbil METEORIC-HF	Acute heart failure	Phase 3	Second Phase 3 trial initiation announced February 21, 2019.
AMG 420	Relapsed. Refractory (R/R) Multiple Myeloma (MM)	Phase 1	Phase 1 data at ASH December 2018 noted 7/42 CRs
AMG 330	Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	Phase 1	Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim)	Immune Thrombocytopenia (Pediatric)	Approved	FDA approval announced December 14, 2018.
Nplate (Romiplostim)	Immune thrombocytopenia (ITP)	sNDA Filing	sNDA filing announced December 19, 2018.
KYPROLIS (CANDOR)	Multiple Myeloma	Phase 3	Phase 3 data due 2019.
AMG 594	Healthy volunteers	Phase 1	Phase 1 trial initiation announced February 20, 2019.

AMPE Ampio Pharmaceuticals Inc.

$0.56

-0.01  -2.16%

111.1 million

$62 million

30.18

349.8 thousand

565 thousand

0.62

$11.15

$0.54

$0.57

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Ampion	Osteoarthritis of the Knee	Phase 3	Noted August 7, 2018 that further trials required before filing BLA, confirmed December 13, 2018.
Optina	Diabetic Macula Edema	Phase 2b	Phase 2b data released May 2015 did not meet endpoints

AMPH Amphastar Pharmaceuticals Inc.

$20.49

+0.33  +1.64%

46.8 million

$958.7 million

61.9 thousand

206 thousand

0.3

$2.88

$20.16

$20.16

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Albuterol DPI	Asthma	Phase 2b
Naloxone Intranasal	Opioid overdose	CRL	CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol)	Asthma	CRL	CRL issued December 27, 2016.

AMRN Amarin Corporation plc

$17.42

-0.09  -0.51%

329.3 million

$5.7 billion

2.8 million

8.4 million

0.33

$43.55

$17.35

$17.51

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Vascepa REDUCE-IT outcomes trial	High Triglycerides With Mixed Dyslipidemia	sNDA Filing	sNDA filing due late 1Q 2019. New data March 18, 2019 noted 30% risk reduction in total cardiovascular events compared to placebo.

AMRX Amneal Pharmaceuticals Inc. Class A

$13.93

-0.12  -0.85%

298.7 million

$4.2 billion

11.73

307.4 thousand

866.1 thousand

0.35

$8.24

$14.09

$14.05

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
IPX203	Parkinson's disease	Phase 3	Phase 3 data due 1H 2020.

ANAB AnaptysBio Inc.

$68.85

-2.32  -3.26%

27 million

$1.9 billion

110.1 thousand

271.5 thousand

0.41

$3.82

$71.23

$71.17

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ANB020 - etokimab	Moderate-to-severe adult atopic dermatitis	Phase 2b	Phase 2b data due 2H 2019.
ANB020 - etokimab	Severe adult eosinophilic asthma	Phase 2a	Phase 2a full data due 2019. Phase 2b trial to be initiated also in 2019.
ANB019	Palmo-plantar pustular psoriasis	Phase 2	Phase 2 data due 2H 2019.
ANB019	Generalized pustular psoriasis	Phase 2	Phase 2 data due mid-2019.
ANB020 - etokimab	Nasal polyps	Phase 2	Phase 2 data due 2H 2019.

ANCN Anchiano Therapeutics Ltd.

$6.99

+0.03  +0.43%

5.8 million

$40.3 million

7 thousand

0

$699.00

$7.05

$6.96

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Inodiftagene - Codex	Non-muscle invasive bladder cancer (NMIBC)	Phase 2	Phase 2 pivotal initial data due mid-2019.
Inodiftagene with BCG - Leo	Non-muscle invasive bladder cancer (NMIBC)	Phase 3	Phase 3 planned for 2019.

ANIK Anika Therapeutics Inc.

$29.51

+0.09  +0.31%

14.2 million

$419.4 million

63.5 thousand

170.7 thousand

0.37

$1.59

$29.54

$29.42

03/25/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Cingal	Osteoarthritis	Phase 3	Phase 3 trial did not meet primary endpoint - June 19, 2018. Noted February 21, 2019 that further Phase 3 trial is required.
Monovisc	Osteoarthritis	Approved	Approved Feb 2014
HYALOFAST	Cartilage defects of the knee	Phase 3	Phase 3 enrollment to be completed by the end of 2018.

ANIX Anixa Biosciences Inc.

$4.55

-0.14  -2.93%

19.6 million

$89.4 million

28 thousand

70 thousand

0.4

$16.26

$4.72

$4.69

03/25/2019

Drug	Indication	Stage	News

APHB AmpliPhi Biosciences Corporation

$0.31

-0.02  -7.55%

32.3 million

$9.9 million

0.6

1.1 million

410.9 thousand

2.67

$1.45

$0.35

$0.33

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AB-SA01	S. aureus bacteremia	Phase 2	Phase 1/2 trial planned for 2019.

APLS Apellis Pharmaceuticals Inc.

$19.13

+0.23  +1.22%

56.3 million

$1.1 billion

98.8 thousand

432.9 thousand

0.23

$6.69

$18.88

$18.90

03/25/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
APL-2 subcutaneous	Complement-dependent Nephropathies (CDN)	Phase 2	Phase 2 data due 2019.
APL-2 subcutaneous	Auto-immune Hemolytic Anemia (AIHA)	Phase 2	Phase 2 data presented at ASH 2018.
APL-2 PHAROAH	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1b	Phase 1b trial ongoing.
APL-2 OAKS	Geographic atrophy (GA) associated with age-related macular degeneration (AMD)	Phase 3	Phase 3 resumption of enrolment announced March 4, 2019. Enrolment to be completed 1Q 2020.
APL-2 subcutaneous	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 data due 4Q 2019.
APL-2 PADDOCK	Paroxysmal Nocturnal Hemoglobinuria	Phase 1	Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.

APTO Aptose Biosciences Inc.

$2.23

-0.09  -3.88%

41.5 million

$92.5 million

411.7 thousand

306.6 thousand

1.34

$6.56

$2.39

$2.32

03/25/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
APTO-253	Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)	Phase 1b	Phase 1b clinical hold released June 29, 2018. First patient of re-initiation announced November 26, 2018. To be completed in 2019.

APTX Aptinyx Inc.

$4.26

-0.1  -2.29%

33.6 million

$143 million

377.6 thousand

436.9 thousand

0.86

$0.96

$4.35

$4.36

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
NYX-458	Parkinson’s Disease Cognitive Impairment (healthy volunteers)	Phase 1	Phase 1 data due 1H 2019.
NYX-2925	Fibromyalgia	Phase 2	Phase 2 full data due 1H 2019.
NYX-2925	Neuropathic Pain Associated with Diabetic Peripheral Neuropathy	Phase 2	Phase 2 data released January 16, 2019 - primary endpoint not met.
NYX-783	Post-traumatic stress disorder (PTSD)	Phase 2	Phase 2 trial initiation announced February 19, 2019 with data due 1H 2020.

APVO Aptevo Therapeutics Inc.

$0.96

+0.06  +6.04%

42.9 million

$41.4 million

2.1 million

504.4 thousand

4.23

$1.36

$0.93

$0.91

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
APVO414	Castration-resistant prostate cancer	Phase 1	Development terminated - noted November 14, 2018.
Otlertuzumab	Relapsed or refractory peripheral T-cell lymphoma	Phase 2	Development terminated - noted November 14, 2018.
APVO436	Acute myeloid leukemia (AML)	Phase 1	Phase 1anti-drug antibody (ADA) read-out due 3Q 2019, preliminary safety data due 4Q 2019
APVO210	Healthy volunteers	Phase 1	Phase 1 trial initiation announced March 20, 2019 with initial single ascending doses (SAD) data due 3Q and safety data 4Q 2019.

AQST Aquestive Therapeutics Inc.

$6.24

+0.02  +0.32%

25 million

$155.8 million

66.6 thousand

118 thousand

0.56

$15.60

$6.26

$6.22

03/25/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Exservan (riluzole) Oral Film	Amyotrophic Lateral Sclerosis	Phase 3	NDA filing due January 2019.
Sympazan	Lennox-Gastaut Syndrome	Approved	Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203	Epileptic seizures	Phase 3	NDA filing due early 2019.
AQST-119	Erectile dysfunction	CRL	CRL issued November 16, 2018.
APL-130277	Parkinson’s Disease with motor fluctuations	CRL	CRL issued January 30, 2019 through partner Sunovion (private company).

AQXP Aquinox Pharmaceuticals Inc.

$2.69

-0.03  -1.10%

23.5 million

$63.3 million

55.2 thousand

85.2 thousand

0.65

$0.87

$2.73

$2.72

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Rosiptor (AQX-1125)	Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Phase 2	Phase 2 trial has been discontinued.
AQX-1125 LEADERSHIP	Bladder pain syndrome/interstitial cystitis (BPS/IC)	Phase 3	Phase 3 data released June 27, 2018. Primary endpoint not met.
AQX-1125 KINSHIP	Atopic dermatitis (AD)	Phase 2	Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 FLAGSHIP	Chronic obstructive pulmonary disease (COPD)	Phase 2	Phase 2 trail failed - July 2015

ARAV Aravive Inc.

$8.12

-0.14  -1.75%

11.3 million

$91.6 million

13.2 thousand

29.4 thousand

0.45

$1.53

$8.25

$8.26

03/25/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
VRS-317 VELOCITY	Growth hormone deficiency, or GHD - pediatric	Phase 3	Phase 3 top-line data released September 21, 2017 - primary endpoint not met.
AVB-S6-500	Ovarian cancer	Phase 1b	Phase 1b initial safety data due 3Q 2019.

ARDM

$0.00

  +0.00%

$

0

$0.00

$0.00

$0.00

02/20/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Sumavel	Migraine	Approved	Approval granted July 16, 2009.
Linhaliq (Pulmaquin)	Non-cystic fibrosis bronchiectasis (non-CF BE).	CRL	Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.

ARDS Aridis Pharmaceuticals Inc.

$10.63

-0.96  -8.28%

8.1 million

$86.2 million

2.7 thousand

4.7 thousand

0.58

$2.75

$11.49

$11.59

03/25/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AR-301 (Salvecin)	Staphylococcus aureus	Phase 3	Phase 3 trial to be initiated 4Q 2018,
AR-105 (Aerucin)	Pseudomonas aeruginosa	Phase 2	Phase 2 interim data due mid-2019.
AR-101 (Aerumab)	Pseudomonas aeruginosa	Phase 2